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Summary: In this study the analytical performances of two recently introduced assays for soluble transferrin
receptors in serum were tested. The Ramco transferrin assay was compared with the Eurogenetics assay. In a small
clinical study serum samples from patients with anaemia of chronic disease, iron deficiency and myelodysplastic
syndrome were analysed, as well as sera from healthy volunteers. The analytical performances of the Ramco assay
were found to be acceptable. In the Eurogenetics test however, inter-assay imprecision and the end of run drift were
unacceptably high.
We were able to confirm that in patients with uncomplicated iron deficiency the concentration of soluble transferrin
receptors is higher than in healthy volunteers. In cases of anaemia of chronic and inflammatory disease, the levels
of soluble transferrin receptors in serum are slightly, but not significantly, higher than in normal subjects. Measure-
ment of soluble transferrin receptors in serum provides a good differentiation between anaemia of chronic disease
and iron deficiency.
Introduction
Iron is one of the most important elements in the human
body. It is essential for cellular growth and metabolism.
However, an excess of iron can lead to intracellular
damage to DNA and proteins by producing free radicals
in combination with oxygen (1). To prevent damage
from these radicals iron is transported complexed to
transferrin.
The transferrin receptor is a transmembrane protein pre-
sent in all body cells (fig. 1) (1, 2). It consists of two
Fig. 1 The transferrin receptor is a dimer of two identical Λ/Γ
95 000 polypeptides. Each monomer can be divided into
(i) a large extracellular region (empty box) with a number of sugar
residues (1) attached to the C-terminal end,
identical domains. Each domain is capable of binding
two molecules of transferrin. The affinity of the receptor
for transferrin depends on the saturation of transferrin
with iron and is especially high for completely saturated
transferrin. The number of cellular transferrin receptors
depends on the cell's need for iron. The production of
the transferrin receptor is regulated on the level of RNA
by the intracellular iron content (fig. 2). Depending on
this concentration either the iron storage protein ferritin
or the transferrin receptor is produced. Various proteins,
the so called iron binding proteins, can influence these
Extracellular compartment
Plasma membrane
Intracellular compartment
(ii) a small and hydrophobic intermediate segment (grey box) that
spans the plasma membrane and
(in) a short cytoplasmic "tail" containing a phosphorylation site
(P).
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Fig. 2 Schematic presentation of the interaction between the iron- this interaction. Depending on the intracellular iron concentration
responsive element and the iron binding protein and the effects of either ferritin or the transferrin receptor is produced,
fl Iron responsive element n Iron responsive element-binding protein
processes. An excess of iron binding to the iron respon-
sive elements facilitates the translation of RNA coding
for the ferritin molecule. In intracellular iron deficiency,
a decreased binding of iron to these proteins leads to the
translation of that part of the RNA which codes for the
transferrin receptor.
Soluble transferrin receptors in serum are found as a
truncated fragment of transmembrane transferrin recep-
tors (3, 4). The level of soluble transferrin receptors is
directly proportional to the total mass of tissue receptors
(2). Since most of the tissue receptors can be found on
erythroid precursor cells, the number of transferrin re-
ceptors in serum is directly proportional to erythroid ac-
tivity (5). In cases of erythroid hyperplasia, as in iron
deficiency and haemolyic anaemia, the level of soluble
transferrin receptors is raised. In cases of bone marrow
aplasia the level is sharply reduced.
Recently the concentration of soluble transferrin recep-
tors in serum was postulated as a new quantity in the
diagnosis of anaemia caused by iron deficiency (5-7).
A possible role for soluble transferrin receptors in the
differentiation of anaemia of chronic disease from iron
deficiency could be expected and has been described
(8-10).
In the present study, the analytical performances of two
recently introduced soluble transferrin assays were
tested. Serum samples from patients with anaemia of
chronic and inflammatory diseases, iron deficiency and
myelodysplastic syndromes were analysed, as well as
sera from healthy volunteers. A bone marrow aspirate
was taken from every patient in order to establish the
amount of stainable iron, which serves as the gold stan-
dard for total body iron stores.
Materials
Test procedure
The Ramco transferrin receptor kit was obtained from DPC, Apel-
doorn, the Netherlands. The Eurogenetics assay was obtained from
Eurogenetics, Tessenderlo, Belgium.
Both the Ramco and the Eurogenetics transferrin receptor kits are
enzyme immunoassays (EIA) based upon the double antibody
sandwich method. They differ in the dilution of the samples and
in the incubation time. In the Ramco test, samples are prediluted
100-fold and in the Eurogenetics assay 10-fold. The incubation
time in the Ramco test is one hour and in the Eurogenetics test
only 20 minutes. Results are expressed as kU/1 in the Eurogenetics
assay and in mg/1 in the Ramco test. The assay procedures were
followed according to the instructions of the manufacturers.
Apparatus
Precision pipettes: reference pipettes were obtained from Eppen-
dorf, Germany.
Microplates were washed in a microtitration plate washer 1296-
024 from Wallac, Finland.
Microtitre plates were analysed in the microplate absorption pho-
tometer type ht II from Anthos, Austria.
Patients
Serum samples and freshly drawn bone marrow aspirates of pa-
tients with 3 forms of anaemia were studied. Serum samples were
stored at —80 °C until analysis. Bone marrow cells were obtained
from the sternum or crista iliaca and analysed immediately. The
diagnosis of anaemia of chronic disorder, iron deficiency or myelo-
dysplastic syndrome was based on morphological criteria com-
bined with clinical and chemical data. For the diagnosis of anaemia
of chronic disorder (17 patients), patients were classified based on
the clinical syndrome combined with
a) a low haemoglobin concentration*
b) a low iron content in serum and
c) the classic combination in bone marrow aspirates of high levels
of stainable iron in the macrophages of the myelodysplastic syn-
drome and the absence of iron in erythroblasts.
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Iron deficiency (10 cases) was defined by the combination of
a) a low haemoglobin concentration, low iron content in serum,
b) a low ferritin concentration and
c) morphological criteria like microcytic anaemia and absence of
bone marrow iron in morphological staining techniques.
The diagnosis of myelodysplastic syndrome (10 cases) was based
on the morphological criteria of the latest French American British
(FAB) classification (11). All bone marrow aspirates were judged
by a panel of morphologists. Patients diagnosed with chronic my-
elo-monocytic leukaemia were excluded from the study, as well as
patients with refractive anaemia with excess of blasts in trans-
formation (RAEBt).
Serum samples from 62 healthy volunteers were taken as normal
controls.
Staining procedures
Bone marrow aspirates were examined on a slide stained with May
Grünwald Giemsa.
Iron content was estimated by the Prussian blue reaction.
Statistics
For statistical analysis a Student-test was performed.
Regression analysis according to Passing & Bablok was performed
using commercial software Eval-kit 3.1, CKCHL, Elisabeth Zie-
kenhuis, Tilburg, The Netherlands.
Results
Intra-assay imprecision
In the three samples a mean serum transferrin receptor
concentration of 1.9 mg/1, 6.2 mg/1 and 12.1 mg/1 was
found.
Using these samples an intra-assay imprecision of 5.4%,
3.5% and 4.5%, respectively, was found in the Ramco
assay. In the Eurogenetics assay, variability was 4.7%,
7.4% and 11.1%, respectively.
Inter-assay imprecision
Three serum samples were used with a mean concentra-
tion of soluble transferrin receptors of 2.3 mg/1, 6.0 mg/1
and 12.0 mg/1, respectiveliy.
Using these samples, an inter-assay imprecision of
9.0%, 5.5% and 5.4% was found in the Ramco assay. In
the Eurogenetics assay these values were 23.7%, 14.7%
and 19.5%. A mean end of run drift of 4.1%, 5.5% and
10.6% in the Ramco assay and a mean end of run drift
of 13.9%, 10.9% and 14.4% in the Eurogenetics assay
were found. In individual runs, the end of run drift after
6 strips could rise to 24% in the Eurogenetics assay.
Methods
Intra-assay imprecision
To determine the intra-assay imprecision ten replicate measure-
ments on three serum samples were performed.
Inter-assay imprecision
Duplicate measurements on 3 serum samples were performed in
order to determine the inter-assay imprecision. Each sample was
analysed in five different assays over a period of five weeks. Each
serum was divided into five aliquots before freezing to prevent
freeze-thaw instability of the receptor.
Additionally the end of run drift was determined by analysing the
same samples in the first wells as well as in the last wells of the
microplate (Ramco) or in the last wells of six strips (Eurogenetics).
Analytical sensitivity
The zero standard was determined ten times along with the set of
standards and controls. The lowest detectable transferrin receptor
concentration was considered as the mean absorbance of the zero
standard plus two times the standard deviation.
Assay linearity
Serial dilutions of serum samples were measured. Serum samples
were diluted with zero standard from 1-fold to 10-fold.
Method comparison
Regression analysis was performed according to the procedure de-
scribed by Passing & Bablok (12).
Reference values
To find the normal values, 62 sera of healthy volunteers were ana-
lysed. The normal range was defined as the mean value ± 2 SD.
Analytical sensitivity
The detection limits of transferrin receptor are 0.2 mg/I
in the Ramco assay and 31 kU/1 in the Eurogenetics as-
say.
Assay linearity
In the Ramco assay the recovery after dilution was
108% for 1-fold to 10-fold diluted samples. In the Euro-
genetics assay the recovery was 114% for 1-fold and
126% for 10-fold dilution.
Method comparison
Regression analysis showed a linear correlation between
both tests; r = 0.863 (fig. 3).
Clinical significance
For the Ramco assay we found a normal range of 4.94
± 1.64 mg/1. In the Eurogenetics assay the normal range
was 351 ±200kU/l.
We analysed 17 sera from patients with anaemia of
chronic and inflammatory diseases, 10 sera of patients
with proven iron deficiency and 10 sera of patients with
myelodysplastic syndrome; the results are shown in ta-
ble 1. In iron deficiency the mean transferrin receptor
concentration was significantly higher than in normal
subjects. In anaemia of chronic and inflammatory dis-
ease the mean concentration was significantly lower
than in iron deficiency, and it did not differ significantly
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Fig. 3 Method comparison by regression analysis performed ac-
cording to Passing & Bablok. Results of the Ramco assay are ex-
pressed as mg/l, the Eurogenetics assay as kU/1 (103 U/l).
from that of normal subjects. In myelodysplastic syn-
drome the range was very wide but exclusion of the two
most extreme values resulted in a mean concentration
which was not significantly different from that of nor-
mal subjects.
Discussion
The analytical performances of two commercially avail-
able assays for soluble transferrin receptors in serum
were studied. In addition, the clinical significance of the
results was assessed. The testkit distributed by Eurogen-
etics was easier to use than the Ramco assay, but the
analytical performances of the Eurogenetics assay were
unacceptable. The combination of a high inter-assay im-
precision and a high end of run drift makes the assay
useless in a routine laboratory, although increasing the
incubation time to one hour increasing the dilution of
the sample might improve the results. The manufacturer
recommends that only 6 strips be tested in one run.
However, an end of run drift of 24% within the first 6
strips was still found. Analysing only 6 strips in one run
makes the test much more expensive than the Ramco
Tab. 1 Serum transferrin receptor levels in normal subjects and
in patients with iron deficiency, myelodysplastic syndrome and
anaemia of chronic and inflammatory disease.
Diagnosis No. Transferrin
of receptor
cases (mg/l)
Range p-Value
Normal subjects 62
Iron deficiency 10
Myelodysplastic 10
syndrome
Anaemia of
chronic disease
17
4.94 ± 0.82 3.4-7.0 <0.01
12.23 ±2.03 10.0-15.8 -
11.61 ± 11.63 4.2->40 <0.01
5.84 ±1.95 3.0-8.7 <0.01
test because a standard curve has to be established in
every run.
The analytical performance of the Ramco assay was bet-
ter. We found intra- and inter-assay imprecisions that
were slightly higher or the same as those given by the
manufacturer.
In the Ramco assay the results are expressed in mg/l,
which makes the results comparable to previously pub-
lished data. In contrast, the Eurogenetics assay express
the results in kU/1. In the past, standardisation of
soluble transferrin receptor assays has been problem-
atic, because purified transferrin receptors were not
available.
Diagnosis of an uncomplicated iron deficiency is usually
straightforward. Serum ferritin is a reliable blood con^
stituent for predicting bone marrow iron stores. Predic-
tion of the iron content in bone marrow from the ferritin
concentration in serum is less reliable in inflammatory
disease, in cancer, and liver disease. In these cases se-
rum ferritin is often raised as a result of the acute-phase
reaction. Serum ferritin parallels other proteins, such as
C-reactive, in the acute-phase reaction. Often a bone
marrow aspirate has to be taken to establish the diagno-
sis of anaemia of chronic disease. Therefore it would be
valuable to have a new quantity for the differentiation
of iron deficiency from anaemia of chronic and inflam-
matory disease. It has been postulated that the soluble
transferrin receptors in serum could be important in this
differentiation (8).
In this study we were able to confirm that in patients
with uncomplicated iron deficiency the concentration of
soluble transferrin receptors is higher than that in heal-
thy volunteers. In cases of anaemia of chronic and in-
flammatory disease the levels of soluble transferrin re-
ceptors in serum are slightly, but not significantly,
higher than in normal subjects. By measuring soluble
transferrin receptors in serum, a good differentiation be-
tween anaemia of chronic disease and iron deficiency
is possible.
Another diagnostic problem is caused by anaemia asso-
ciated with myelodysplastic syndromes. Myelodysplas-
tic syndromes are a heterogeneous group of disorders in
which anaemia is often the presenting symptom. In the
early phases many patients receive iron to correct their
haemoglobin concentration, leading to a delay in diag-
nosis and accumulation of iron in multiple organs. In
this study soluble transferrin receptors in the sera of pa-
tients with myelodysplastic syndrome were analysed.
The results varied enormously. In most patients normal
levels were seen. However, some individual patients
showed extremely elevated values, even far above the
upper limit found in severe iron deficiency. These results
indicate that in myelodysplastic syndrome, investigation
Kuiper-Kramer: Soluble transferrin receptors in serum 649
of the bone marrow is still required for diagnosis, and
analysis of the soluble serum transferrin receptor is not
helpful.
In conclusion, the results in this study have shown that
the analytical performances of the Ramco assay are ac-
ceptable, whereas those of the Eurogenetics assay are
not. In the latter assay the inter-assay imprecision and
the end of run drift are unacceptably high. Using these
commercial test kits, the present small clinical study
confirms previously published data showing that soluble
transferrin receptors in serum are elevated in uncompli-
cated iron deficiency. Measurement of the concentration
of transferrin receptors in serum can help in the differen-
tiation of subjects with anaemia of chronic and inflam-
matory disease from those with iron deficiency. In the
diagnosis of myelodyplastic syndrome, the soluble
transferrin receptor concentration is of no help, and a
bone marrow aspiration is always required.
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